Structure, Function, and Therapeutic Use of IgM Antibodies

por Keyt, Bruce A., Baliga, Ramesh, Sinclair, Angus M., Carroll, Stephen F., Peterson, Marvin S.
Publicado 2020

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

por Strohl, William R., Ku, Zhiqiang, An, Zhiqiang, Carroll, Stephen F., Keyt, Bruce A., Strohl, Lila M.
Publicado 2022

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199

por Wang, Beatrice T., Kothambawala, Tasnim, Wang, Ling, Matthew, Thomas J., Calhoun, Susan E., Saini, Avneesh K., Kotturi, Maya F., Hernandez, Genevive, Humke, Eric W., Peterson, Marvin S., Sinclair, Angus M., Keyt, Bruce A.
Publicado 2021

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING

por Hart, Kevin C., Santos, Daniel, Pandya, Deepal, Deng, Rong, LI, Keyu, Guan, Yinghui, Hernandez, Genevive, Manley, Thomas, Leabman, Maya K., Hinton, Paul R., Liu, Liqin, Sinclair, Angus M., Candia, Albert F., Carroll, Stephen F., Keyt, Bruce A., Kotturi, Maya F.
Publicado 2023